Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Polish breast cancer treatment patterns revealed in new study

NCT ID NCT05478590

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observed 440 adults in Poland with advanced HR+ HER2- breast cancer to understand how doctors treat the disease in everyday practice. Researchers tracked treatment choices, changes over one year, and how they relate to patient characteristics and guidelines. The goal was to gather real-world data, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

440 people

The number who actually took part.

Started

Nov 2021

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients treated for the locally advanced/metastatic breast cancer of the HR+ HER2- subtype

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with histologically diagnosed advanced breast cancer (with locoregional recurrence not eligible for radical local treatment or with distant metastases) * Patient has a documented hormone (estrogen and/or progesterone) receptor expression and lack of HER2 receptor overexpression or lack of HER2 gene amplification (HR+/HER2- breast cancer subtype) * Patient had no prior treatment for advanced breast cancer * Patient has no symptomatic metastases to the central nervous system * There is no other malignancies in patient requiring active treatment * Patient is without co-occurring other malignancies treated with palliative assumption Exclusion Criteria: * Parallel patient's participation in any other clinical trial at the time when the decision over the advanced breast cancer treatment was made or up to 30 days before it.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

Contacts and locations

Locations

  • Ambulatorium Chemioterapii Centrum Onkologii

    Bydgoszcz, 85-796, Poland

  • Centralny Szpital Kliniczny MSWiA w Warszawie

    Warsaw, 02-507, Poland

  • Dolnośląskie Centrum Onkologii

    Wroclaw, 53-413, Poland

  • Izerskie Centrum Pulmonologii i Chemioterapii "Izer-Med" Sp. z o.o

    Szklarska Poręba, 58-580, Poland

  • Klinika Onkologii, Instytut Centrum Zdrowia Matki Polki

    Lodz, 93-338, Poland

  • Narodowy Instytut Onkologii

    Krakow, 31-115, Poland

  • Oddział Onkologii Klinicznej

    Kalisz, 62-800, Poland

  • Oddział Onkologii Klinicznej z Pododdziałem Dziennym

    Krakow, 31-816, Poland

  • Oddział onkologii Szpital Specjalistyczny im. H. Klimontowicza

    Gorlice, 38-300, Poland

  • Oddział/Poradnia Onkologiczna Wojewodzki Szpital w Przemyślu

    Przemyśl, 37-700, Poland

  • Opolskie Centrum Onkologii

    Opole, 45-061, Poland

  • Pfizer Polska

    Warsaw, Poland

  • Podkarpackie Centrum Onkologii

    Rzeszów, 35-055, Poland

  • SPZOZ Oddział onkologii klinicznej

    Swidnica, 58-100, Poland

  • Specjalistyczny Szpital Onkologiczny NU-MED

    Tomaszów Mazowiecki, 92-700, Poland

  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

    Gdansk, 80-214, Poland

  • Wojewodzki Szpital Specjalistyczny we Wroclawiu

    Wroclaw, 51-124, Poland

  • Wojewodzki Szpital Zespolony w Elblągu - oddzial onkologii

    Elblag, 82-300, Poland

  • Zachodniopomorskie Centrum Onkologii

    Szczecin, 71-730, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.